

**Amendments to the Claims**

Please amend claims 59 and 67 as indicated in the listing of claims.

The listing of claims will replace all prior versions, and listings of claims in the application.

**Listing of Claims:**

1. (Original) A substantially purified human small conductance calcium-activated channel-3 (hKCa3/KCNN3) polypeptide comprising an amino acid sequence as set forth in SEQ ID NO:2.

Claims 2-58 (Canceled)

59. (Currently Amended) A composition comprising:
  - (a) ~~a therapeutically effective amount of~~ a substantially pure hKCa3/KCNN3 polypeptide comprising an amino acid sequence as set forth in SEQ ID NO: 2;  
and
  - (b) a pharmaceutically acceptable carrier.

Claims 60-64 (Canceled)

65. (Previously Presented) The composition of claim 59, wherein the carrier is a liposome.
66. (Previously Presented) The composition of claim 59, wherein the polypeptide is conjugated to a carrier protein.
67. (Currently Amended) The composition of claim ~~666~~ 66, wherein the carrier protein is selected from the group consisting of keyhole limpet hemocyanin (KLH), thyroglobulin, bovine serum albumin (BSA), and tetanus toxoid.